Search

Search Results

• 

  Increased plasma lipocalin-2 levels correlate with disease severity and may be a marker of acute inflammatory response in patients with psoriasis

  Chuyen Thi Hong Nguyen, Oanh Phan Tram Nguyen

  21-11-2022

  https://doi.org/10.4081/dr.2022.9469

  1345

  PDF: 566

  HTML: 43

• Prevalence and association of renal disorders in Saudi adult patients with psoriasis and psoriatic arthritis: a tertiary-center retrospective cross-sectional study

  Mishari T. Alrubaiaan, Abdullah D. Alhobabi, Raghad M. Alharthi, Saad A. Alsulaiman, Abdullah N. Altasan, Ibrahim M. Momen, Mohammad Almohideb

  02-01-2025

  https://doi.org/10.4081/dr.2025.10083

  811

  PDF: 402

  HTML: 33

• Treatment satisfaction among patients with psoriasis in Saudi Arabia

  Mahdi Aldhafiri, Rahaf Almutairi, Reem Albejais, Asma Almubark, Hussain Alwesaibie, Mohammed Albesher, Manayer Almustihi

  15-04-2024

  https://doi.org/10.4081/dr.2024.9967

  1108

  PDF: 611

  HTML: 45
• 

  Erythrodermic psoriasis improved by tildrakizumab

  Giampaolo Trevisan, Lerica Germi, Luigi Naldi

  23-11-2022

  https://doi.org/10.4081/dr.2022.9448

  1322

  PDF: 637

  HTML: 26
• 

  Erythrodermic psoriasis treated with apremilast

  John Arcilla, Daniel Joe, Johnathan Kim, Yohanan Kim, VuAnh N. Truong, Navin Jaipaul

  19-09-2016

  https://doi.org/10.4081/dr.2016.6599

  2186

  PDF: 988

  HTML: 607

• Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

  Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

  30-07-2025

  https://doi.org/10.4081/dr.2025.10379

  542

  PDF: 373

  HTML: 9

• Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab

  Angela Fico, Edoardo Mortato, Claudia Paganini, Marina Talamonti, Cosimo Di Raimondo, Dionisio Silvaggio, Luca Bianchi, Marco Galluzzo

  30-05-2025

  https://doi.org/10.4081/dr.2025.10414

  830

  PDF: 456

  HTML: 38

• Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

  Alba Guglielmo, Maria Ludovica Deotto , Luigi Naldi , Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi

  13-09-2023

  https://doi.org/10.4081/dr.2023.9839

  2834

  PDF: 1007

  HTML: 37
• 

  Mucocutaneous presentations of consultant critical and non-critical cases of admitted COVID-19 patients, outpatients, and vaccine-associated dermatoses: a clinical atlas and a large original study of two general COVID-19 centers from Iran

  Afsaneh Sadeghzadeh-Bazargan, Azadeh Goodarzi

  23-05-2023

  https://doi.org/10.4081/dr.2023.9473

  1023

  PDF: 491

  SUPPLEMENTARY FILE: 164

  HTML: 25

• Refractory pityriasis rubra pilaris treated with abrocitinib

  Filip Rob

  09-01-2025

  https://doi.org/10.4081/dr.2025.10105

  487

  PDF: 316

  HTML: 23

• Bullous pemphigoid with secondary acquired reactive perforating collagenosis: a challenging clinical case report

  Valentina Ruffo di Calabria, Elena Biancamaria Mariotti, Alberto Corrà, Alice Verdelli, Lavinia Quintarelli, Cristina Aimo, Giovanni Di Zenzo, Vincenza Maio, Daniela Massi, Marzia Caproni

  03-10-2024

  https://doi.org/10.4081/dr.2024.10087

  1091

  PDF: 614

  HTML: 100

• Pityriasis following COVID-19 vaccinations: a systematic review

  Laura Duzett, Guadalupe Mercado, Vasiliki Tasouli-Drakou, Alicia Kane, Alison Tam

  09-08-2023

  https://doi.org/10.4081/dr.2023.9742

  1372

  PDF: 771

  Supplementary Material: 154

  HTML: 85